To assess whether Sema6A and Mical-1 were preferentially expressed in BRAFV600E tumors, we analyzed their expression by qRT-PCR and immunohistochemistry (IHC) on BRAFV600E and BRAF wild type (WT) melanoma specimens derived from patients surgically treated at the Regina Elena National Cancer Institute. The gene discussed is SEMA6A; the disease is melanoma.